Calithera Biosciences, Inc. (CALA)
USD 0.01
(4900.0%)
USD 0.01
(4900.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 | 28.67 Million USD | -55.72% |
| 2021 | 64.75 Million USD | -48.44% |
| 2020 | 125.58 Million USD | -25.59% |
| 2019 | 168.76 Million USD | 18.25% |
| 2018 | 142.72 Million USD | -25.84% |
| 2017 | 192.45 Million USD | 251.22% |
| 2016 | 54.79 Million USD | -27.66% |
| 2015 | 75.75 Million USD | -27.7% |
| 2014 | 104.77 Million USD | 200.68% |
| 2013 | 34.84 Million USD | 1038.69% |
| 2012 | 3.06 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2022 Q2 | 45.55 Million USD | -9.31% |
| 2022 Q1 | 50.23 Million USD | -22.42% |
| 2022 FY | 28.67 Million USD | -55.72% |
| 2022 Q4 | 28.67 Million USD | -22.67% |
| 2022 Q3 | 37.08 Million USD | -18.6% |
| 2021 Q2 | 97.85 Million USD | -11.57% |
| 2021 Q1 | 110.65 Million USD | -11.89% |
| 2021 Q3 | 89.97 Million USD | -8.06% |
| 2021 Q4 | 64.75 Million USD | -28.03% |
| 2021 FY | 64.75 Million USD | -48.44% |
| 2020 Q3 | 147.7 Million USD | -10.44% |
| 2020 FY | 125.58 Million USD | -25.59% |
| 2020 Q4 | 125.58 Million USD | -14.98% |
| 2020 Q1 | 149.67 Million USD | -11.31% |
| 2020 Q2 | 164.92 Million USD | 10.19% |
| 2019 Q4 | 168.76 Million USD | 15.34% |
| 2019 Q1 | 131.9 Million USD | -7.58% |
| 2019 FY | 168.76 Million USD | 18.25% |
| 2019 Q3 | 146.31 Million USD | -12.06% |
| 2019 Q2 | 166.37 Million USD | 26.13% |
| 2018 Q3 | 147.67 Million USD | -7.11% |
| 2018 Q2 | 158.97 Million USD | -10.98% |
| 2018 Q1 | 178.58 Million USD | -7.21% |
| 2018 FY | 142.72 Million USD | -25.84% |
| 2018 Q4 | 142.72 Million USD | -3.35% |
| 2017 FY | 192.45 Million USD | 251.22% |
| 2017 Q3 | 205.54 Million USD | -3.99% |
| 2017 Q2 | 214.08 Million USD | -4.39% |
| 2017 Q1 | 223.9 Million USD | 308.62% |
| 2017 Q4 | 192.45 Million USD | -6.37% |
| 2016 Q4 | 54.79 Million USD | -7.01% |
| 2016 FY | 54.79 Million USD | -27.66% |
| 2016 Q2 | 63.22 Million USD | -11.64% |
| 2016 Q3 | 58.92 Million USD | -6.81% |
| 2016 Q1 | 71.56 Million USD | -5.53% |
| 2015 Q3 | 84.53 Million USD | -6.85% |
| 2015 Q2 | 90.74 Million USD | -6.32% |
| 2015 Q1 | 96.87 Million USD | -7.54% |
| 2015 FY | 75.75 Million USD | -27.7% |
| 2015 Q4 | 75.75 Million USD | -10.39% |
| 2014 Q2 | 30.65 Million USD | 0.0% |
| 2014 Q3 | 39.64 Million USD | 29.32% |
| 2014 FY | 104.77 Million USD | 200.68% |
| 2014 Q4 | 104.77 Million USD | 164.29% |
| 2013 FY | 34.84 Million USD | 1038.69% |
| 2013 Q4 | 34.84 Million USD | 0.0% |
| 2012 FY | 3.06 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| America Great Health | 299.12 Thousand USD | -9486.499% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -399.93% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -95.141% |
| Biora Therapeutics, Inc. | 31.21 Million USD | 8.134% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -790.559% |
| Better Therapeutics, Inc. | 22.94 Million USD | -24.988% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -669.389% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -39.583% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -35.757% |
| Evelo Biosciences, Inc. | 64.44 Million USD | 55.5% |
| Evolutionary Genomics, Inc. | 2.35 Million USD | -1118.332% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | 59.61% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -9.697% |
| Innovation1 Biotech Inc. | 75.99 Thousand USD | -37635.055% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -135.648% |
| Molecular Templates, Inc. | 35.38 Million USD | 18.955% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -555.96% |
| NexImmune, Inc. | 8.59 Million USD | -233.677% |
| Orgenesis Inc. | 14.55 Million USD | -97.059% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -142.976% |
| Point of Care Nano-Technology, Inc. | 124.64 Thousand USD | -22906.507% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -404.823% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -7210.364% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | 93.935% |
| Statera Biopharma, Inc. | 21.16 Million USD | -35.458% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -183.78% |
| Trevena, Inc. | 40.6 Million USD | 29.378% |
| Vaxxinity, Inc. | 44.35 Million USD | 35.346% |
| Vaccinex, Inc. | 3.63 Million USD | -689.755% |
| Vicapsys Life Sciences, Inc. | 39.65 Thousand USD | -72211.882% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | 49.418% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -5060.199% |